Zak alpha kinase (map3k20) inhibitors for use in the treatment of anemia

ZAK alpha kinase inhibitors for use, according to any of the previous claims, wherein the congenital anemia is selected from the group comprising:

• Diamond-Blackfan anemia, Fanconi anemia, thalassemia and/or myelodysplastic syndrome.

ZAK alpha kinase inhibitors for use, according to any of the previous claims, in the treatment of Diamond-Blackfan anemia, characterized in that the inhibitor is selected from the group comprising:

• Nilotinib, Dasatinib, Imatinib and/or Bosutinib.

ZAK alpha kinase inhibitors for use, according to any of the previous claims, in the treatment of Diamond-Blackfan anemia, characterized in that the inhibitor is selected from the group comprising:

• Nilotinib and/or Imatinib.

ZAK alpha kinase inhibitors for use, according to any of the previous claims, wherein the inhibitor is a tyrosine kinase inhibitor.

Composition comprising ZAK alpha kinase inhibitors and, optionally, pharmaceutically acceptable excipients or carriers, for use in the treatment of congenital anemia characterized in that the inhibitor is selected from the group comprising:

• Nilotinib, Dasatinib, Imatinib, Ponatinib and/or Bosutinib.

In vitro method for screening, identifying and/or producing compounds for use in the treatment of anemia which comprises:

• a) Assessing ZAK alpha kinase enzyme activity once the candidate compound has been incubated with ZAK alpha kinase enzyme, and b) wherein if an inhibition of ZAK alpha kinase enzyme activity is observed, it is indicative that the candidate compound may be effective in the treatment of anemia.